(19)
(11) EP 2 545 068 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.03.2018 Bulletin 2018/12

(45) Mention of the grant of the patent:
24.01.2018 Bulletin 2018/04

(21) Application number: 11708450.9

(22) Date of filing: 11.03.2011
(51) International Patent Classification (IPC): 
C07K 14/22(2006.01)
(86) International application number:
PCT/EP2011/053665
(87) International publication number:
WO 2011/110655 (15.09.2011 Gazette 2011/37)

(54)

IMMUNOGENIC COMPOSITION OR VACCINE AGAINST GRAM-NEGATIVE BACTERIAL, FOR EXAMPLE NEISERIAL, INFECTION OR DISEASE

IMMUNOGENE ZUSAMMENSETZUNG ODER IMPFSTOFF GEGEN INFEKTION ODER KRANKHEIT MIT GRAM-NEGATIVEN BAKTERIEN WIE Z.B. NEISSERIA

COMPOSITION IMMUNOGÉNIQUE OU VACCIN CONTRE UNE INFECTION OU MALADIE CAUSÉE PAR DES BACTERIES À GRAM-NEGATIF, COMME PAR EXEMPLE NEISSERIA


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 11.03.2010 US 312959 P

(43) Date of publication of application:
16.01.2013 Bulletin 2013/03

(60) Divisional application:
18152692.2

(73) Proprietor: GlaxoSmithKline Biologicals S.A.
1330 Rixensart (BE)

(72) Inventors:
  • DEVOS, Nathalie, Isabelle
    B-1330 Rixensart (BE)
  • POOLMAN, Jan
    B-1330 Rixensart (BE)
  • STORK, Michiel
    NL-3584 CH Utrecht (NL)
  • TOMMASSEN, Johannes, Petrus, Maria
    NL-3584 CH Utrecht (NL)
  • WEYNANTS, Vincent
    B-1330 Rixensart (BE)

(74) Representative: Dalton, Marcus Jonathan William et al
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-00/11182
WO-A1-2010/025964
WO-A2-00/71725
WO-A2-99/57280
WO-A1-2007/148363
WO-A2-00/55327
WO-A2-01/85772
   
  • CHEN ET AL: "Identification and characterization of a high-affinity zinc uptake system in Neisseria gonorrhoeae.", FEMS MICROBIOLOGY LETTERS, vol. 202, no. 1, 1 August 2001 (2001-08-01), pages 67-71, XP55001190, ISSN: 0378-1097 cited in the application
  • PATZER SILKE I ET AL: "The ZnuABC high-affinity zinc uptake system and its regulator Zur in Escherichia coli", MOLECULAR MICROBIOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 28, no. 6, 1 June 1998 (1998-06-01), pages 1199-1210, XP002453143, ISSN: 0950-382X, DOI: DOI:10.1046/J.1365-2958.1998.00883.X cited in the application
  • CAMPOY SUSANA ET AL: "Role of the high-affinity zinc uptake znuABC system in Salmonella enterica serovar typhimurium virulence", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 70, no. 8, 1 August 2002 (2002-08-01) , pages 4721-4725, XP002453141, ISSN: 0019-9567, DOI: DOI:10.1128/IAI.70.8.4721-4725.2002
  • TURNER PAUL C ET AL: "Neisserial TonB-dependent outer-membrane proteins: Detection, regulation and distribution of three putative candidates identified from the genome sequences", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 147, no. 5, 1 May 2001 (2001-05-01), pages 1277-1290, XP009121702, ISSN: 1350-0872 cited in the application & DATABASE UniProt [Online] 1 October 2000 (2000-10-01), "SubName: Full=Putative TonB-dependent outer membrane receptor;", XP002641445, retrieved from EBI accession no. UNIPROT:Q9JR50 Database accession no. Q9JR50
  • VIPOND C ET AL: "Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry", HUMAN VACCINES, LANDES BIOSCIENCE, GEORGETOWN, TX, US, vol. 1, no. 2, 1 January 2005 (2005-01-01) , pages 80-84, XP008085859, ISSN: 1554-8600
  • STORK MICHIEL ET AL: "An Outer Membrane Receptor of Neisseria meningitidis Involved in Zinc Acquisition with Vaccine Potential", PLOS PATHOGENS, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, vol. 6, no. 7, 1 July 2010 (2010-07-01), pages E1000969-1, XP009148766, ISSN: 1553-7366
  • ANONYMOUS: "Vaccines and related biological products advisory committee FDA Briefing Document: Use of Serum Bactericidal Antibody as an Immunological Correlate forDemonstrating Effectiveness of Meningococcal Conjugate Vaccines (SerogroupsA, C, Y, W-135) Administered to Children Less Than 2 Years of Age", FDA BRIEFING DOCUMENT, 6 April 2011 (2011-04-06), pages 1-9,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).